Tag
This study investigates three-year continuous glucose monitoring trajectories across clinical subgroups of adults with type 1 diabetes to identify factors influencing glycemic control and variability, highlighting the need for individualize
The gain-of-function GLP1R R131Q variant slows β-cell decline and improves glycemic response to GLP-1 receptor agonists, highlighting its potential role in precision diabetes therapeutics.
Baricitinib treatment in recent-onset type 1 diabetes preserves β-cell function during therapy. However, this effect diminishes within a year after stopping treatment, highlighting the need for sustained immunotherapy for lasting benefit.
Serial dried blood spot C-peptide sampling detects early β-cell preservation in new-onset type 1 diabetes more sensitively than urine C-peptide-to-creatinine ratio or mixed-meal tolerance test.
The PRISM trial evaluated a precision medicine program using biogenetic markers and multidisciplinary care in Chinese young-onset diabetes patients, improving metabolic control and patient well-being but not reducing complications over thre
This study evaluates the clinical benefits of semaglutide, a GLP-1 receptor agonist, as an add-on therapy to insulin in patients with LADA, demonstrating improved glycemic control, BMI reduction, and insulin dose sparing, especially in thos
Recent trials suggest that time-restricted eating (TRE) may modestly improve β-cell function and metabolic control in type 2 diabetes, but effects on insulin sensitivity and long-term outcomes remain uncertain.
